Alzheimer's Disease

Utilizing a recently developed brain imaging technique new research suggests measuring accumulated levels of a protein called tau may predict future neurodegeneration associated with Alzheimer’s disease.

A new study has described the successful results in mice of a novel vaccine designed to prevent neurodegeneration associated with Alzheimer’s disease. The researchers suggest this "dementia vaccine" could become the “breakthrough of the next decade.”

Results have been published from one of the first placebo-controlled clinical trials investigating the effects of microdosing LSD. This Phase 1 trial is exploring whether microdosing could be useful as a therapeutic tool to treat Alzheimer’s disease.

Scientists are homing in on exactly how two experimental Alzheimer’s drugs may be generating the anti-aging effects seen in animal studies. The discovery of a unique metabolic pathway offers researchers novel directions for future anti-aging studies.

A once-promising anti-Alzheimer’s drug failed in final clinical trials early in 2019, but now the company producing it is claiming it analyzed the data incorrectly. The drug actually works, it says, and all eyes are now on the FDA’s approval process.

Two compelling new studies are building on a hypothesis suggesting age-related dementia is caused by a leaky blood-brain barrier. Experts suggest the studies are interesting but not particularly applicable to human cases of dementia.

A team of international researchers has achieved a world-first breakthrough, decades in the making, creating artificial neurons with the ability to behave exactly like real living neurons. The innovation has potential for treating numerous diseases.

A leading suspect in the onset of Alzheimer's disease is a toxic plaque called amyloid-beta, which new research has found could be better cleared away by harnessing natural oscillations in the blood vessels known as vasomotion.

A study, from Sweden’s Karolinska Institutet, has demonstrated a new method that can distinguish between two different, but closely related, strains of the herpes virus, offering evidence to suggest the virus plays a role in multiple sclerosis.

Several new studies are reporting evidence affirming a growing hypothesis that links inflammation with the cognitive deficits seen in bipolar disorder and Alzheimer’s. It's also suggested low-grade inflammation can result in mental sluggishness.

Chinese authorities recently approved a novel drug claimed to improve cognitive function in patients with Alzheimer’s disease. Derived from a seaweed, it's suggested to reduce neuroinflammation by modulating a person’s gut microbiome.

In an unusual turn of events a new Alzheimer’s drug, previously declared a failure in March, has been resurrected with the pharmaceutical company behind the treatment suggesting the earlier decision was premature and based on incorrect data analysis.